Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.
Emma ZattarinDaniele PrestiLuigi MarianiCaterina SposettiRita LeporatiAlice MenichettiChiara CortiChiara BenvenutiGiovanni FucàRiccardo LobefaroFrancesca LigorioLeonardo ProvenzanoAndrea VingianiMarta Del VecchioGaia GriguoloMarianna SiricoOttavia BernocchiAntonio MarraPaola ZagamiElisa AgostinettoFlavia JacobsPierluigi di MauroAndrea EspositoCarlo Alberto GiorgiLuca LalliLaura BoldriniPier Paolo Berton GiacchettiAmbra Carnevale SchiancaValentina GuarneriRebecca PedersiniAgnese LosurdoAlberto ZambelliDaniele GeneraliCarmen CriscitielloCurigliano GiuseppeGiancarlo PruneriFilippo de BraudMaria Vittoria DieciClaudio VernieriPublished in: NPJ breast cancer (2023)
Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.